Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Yuanchao Zhu, Fei Zhao & Pengfei Jin. (2023) Clinical Manifestations and Risk Factors of Tigecycline-Associated Thrombocytopenia. Infection and Drug Resistance 16, pages 6225-6235.
Read now
Read now
Daniele Roberto Giacobbe, Vincenzo Di Pilato, Ilias Karaiskos, Tommaso Giani, Anna Marchese, Gian Maria Rossolini & Matteo Bassetti. (2023) Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades. Annals of Medicine 55:1, pages 101-113.
Read now
Read now
Burcu Isler, Abdullah Tarık Aslan, Murat Akova, Patrick Harris & David L. Paterson. (2022) Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections. Expert Review of Anti-infective Therapy 20:11, pages 1389-1400.
Read now
Read now
Matteo Bassetti, Alessandro Russo, Alessia Carnelutti, Alessandro La Rosa & Elda Righi. (2018) Antimicrobial resistance and treatment: an unmet clinical safety need. Expert Opinion on Drug Safety 17:7, pages 669-680.
Read now
Read now
Joshua T. Thaden, Jason M. Pogue & Keith S. Kaye. (2017) Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 8:4, pages 403-416.
Read now
Read now
José Garnacho-Montero, Rosario Amaya-Villar, Carmen Ferrándiz-Millón, Ana Díaz-Martín, José María López-Sánchez & Antonio Gutiérrez-Pizarraya. (2015) Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia. Expert Review of Anti-infective Therapy 13:6, pages 769-777.
Read now
Read now
Ilias Karaiskos & Helen Giamarellou. (2014) Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opinion on Pharmacotherapy 15:10, pages 1351-1370.
Read now
Read now
Articles from other publishers (43)
Matteo Rinaldi, Cecilia Bonazzetti, Mena Gallo, Giuseppe Ferraro, Maristela Freire, Débora Raquel Benedita Terrabuio, Francesco Tandoi, Renato Romagnoli, Francesco Giuseppe De Rosa, Alessandra Mularoni, Alberto Ferrarese, Patrizia Burra, Marcia Halpern, Elizabeth Balbi, Jacques Simkins, Lilian Abbo, Ignacio Morrás, Mireia Cantero, Laura Alagna, Alessandra Bandera, Wanessa Trinidade Clemente, Maricela Valerio, Ainhoa Fernández, Patricia Muñoz, Liran Statlender, Dafna Yahav, Luis Fernando Aranha Camargo, Evelyne Santana Girão, Paolo Grossi, Pierluigi Viale, Stefania Curti & Maddalena Giannella. (2023) Validation of the INCREMENT‐SOT‐CPE score in a large cohort of liver transplant recipients with carbapenem‐resistant Enterobacterales infection. Transplant Infectious Disease 25:2.
Crossref
Crossref
Maria Kipourou, Olga Begou, Katerina Manika, Georgios Ismailos, Paschalina Kontou, Georgia Pitsiou, Helen Gika & Ioannis Kioumis. (2023) Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation. Antibiotics 12:2, pages 307.
Crossref
Crossref
Mical Paul, Elena Carrara, Pilar Retamar, Thomas Tängdén, Roni Bitterman, Robert A. Bonomo, Jan de Waele, George L. Daikos, Murat Akova, Stephan Harbarth, Celine Pulcini, José Garnacho-Montero, Katja Seme, Mario Tumbarello, Paul Christoffer Lindemann, Sumanth Gandra, Yunsong Yu, Matteo Bassetti, Johan W. Mouton, Evelina Tacconelli & Jesús Rodríguez-Baño. (2022) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection 28:4, pages 521-547.
Crossref
Crossref
Soma Gaur & Abhijit M Bal. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
136
153
.
Lei Zha, Dayan Zhang, Lingling Pan, Zhichu Ren, Xiang Li, Yi Zou, Shirong Li, Shuangqi Luo, Gang Yang & Boris Tefsen. (2021) Tigecycline in the Treatment of Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia: A Multicenter Retrospective Cohort Study. Infectious Diseases and Therapy 10:4, pages 2415-2429.
Crossref
Crossref
Jean Gibb & Darren W. Wong. (2021) Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies. Antibiotics 10:10, pages 1226.
Crossref
Crossref
Andrew Burke, Daniel Smith, Chris Coulter, Scott C. Bell, Rachel Thomson & Jason A. Roberts. (2021) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis. Clinical Pharmacokinetics 60:9, pages 1081-1102.
Crossref
Crossref
Alpaslan TANOĞLU & Eylem ÇAĞILTAY. (2021) Tigecycline induced acute pancreatitis: Suspicion is the first step in diagnosis. Anatolian Current Medical Journal 3:3, pages 262-263.
Crossref
Crossref
Zhen Hui, Shiyi Liu, Ruiqin Cui, Biao Zhou, Chunxia Hu, Min Zhang, Qiuyang Deng, Shumin Cheng, Yutian Luo, Huaisheng Chen, Jinsong Wu, Yuemei Lu, Xueyan Liu, Lingyun Dai & Wei Huang. (2021) A small molecule interacts with pMAC-derived hydroperoxide reductase and enhances the activity of aminoglycosides. The Journal of Antibiotics 74:5, pages 324-329.
Crossref
Crossref
Corneliu Ovidiu Vrancianu, Elena Georgiana Dobre, Irina Gheorghe, Ilda Barbu, Roxana Elena Cristian & Mariana Carmen Chifiriuc. (2021) Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections. Microorganisms 9:4, pages 730.
Crossref
Crossref
Weijin Fang, Dan Yi, Linli Sun & Chunjiang Wang. (2020) Analysis of clinical characteristics of tigecycline‐induced acute pancreatitis. Journal of Clinical Pharmacy and Therapeutics 45:6, pages 1320-1324.
Crossref
Crossref
Lei Zha, Lingling Pan, Jun Guo, Neil French, Elmer V. Villanueva & Boris Tefsen. (2020) Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis. Advances in Therapy 37:3, pages 1049-1064.
Crossref
Crossref
Ilias Karaiskos & Helen Giamarellou. (2020) Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics 9:2, pages 61.
Crossref
Crossref
Qiaomei Fan, Wei Huang, Yayun Weng, Xianze Xie & Zheng Shi. (2020) Hypofibrinogenemia induced by high-dose tigecycline—case report and review of literature. Medicine 99:43, pages e22638.
Crossref
Crossref
Juan David Plata & Ximena Castañeda. 2020. Oncologic Critical Care. Oncologic Critical Care
1323
1335
.
Xiaoyan Cui, Haifang Zhang & Hong Du. (2019) Carbapenemases in Enterobacteriaceae: Detection and Antimicrobial Therapy. Frontiers in Microbiology 10.
Crossref
Crossref
Suay-García & Pérez-Gracia. (2019) Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. Antibiotics 8:3, pages 122.
Crossref
Crossref
Ilias Karaiskos, Styliani Lagou, Konstantinos Pontikis, Vasiliki Rapti & Garyphallia Poulakou. (2019) The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Frontiers in Public Health 7.
Crossref
Crossref
Marilyn C. Roberts. 2019. Bacterial Resistance to Antibiotics – From Molecules to Man. Bacterial Resistance to Antibiotics – From Molecules to Man
101
124
.
Jinhong Gong, Dan Su, Jingjing Shang, Hai Yu, Guantao Du, Ying Lin, Zhiqiang Sun & Guangjun Liu. (2019) Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases. Medicine 98:38, pages e17091.
Crossref
Crossref
Juan David Plata & Ximena Castañeda. 2019. Oncologic Critical Care. Oncologic Critical Care
1
13
.
A. Broeker, S. G. Wicha, C. Dorn, A. Kratzer, M. Schleibinger, F. Kees, A. Heininger, M. G. Kees & H. Häberle. (2018) Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. Critical Care 22:1.
Crossref
Crossref
T. Amat, A. Gutiérrez-Pizarraya, I. Machuca, I. Gracia-Ahufinger, E. Pérez-Nadales, Á. Torre-Giménez, J. Garnacho-Montero, J.M. Cisneros & J. Torre-Cisneros. (2018) The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clinical Microbiology and Infection 24:6, pages 630-634.
Crossref
Crossref
Jesús Rodríguez-Baño, Belén Gutiérrez-Gutiérrez, Isabel Machuca & Alvaro Pascual. (2018) Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clinical Microbiology Reviews 31:2.
Crossref
Crossref
J. Wach, A. Dinh, H. Dutronc, O.R. Sipahi, A. Candevir, F. Valour, V. Zeller, S. Lustig, F. Laurent, C. Chidiac & T. Ferry. (2018) Tigecycline-based prolonged salvage therapy in patients presenting with complex bone and joint infection. Médecine et Maladies Infectieuses 48:1, pages 53-57.
Crossref
Crossref
M. Bassetti, D.R. Giacobbe, H. Giamarellou, C. Viscoli, G.L. Daikos, G. Dimopoulos, F.G. De Rosa, E.J. Giamarellos-Bourboulis, G.M. Rossolini, E. Righi, I. Karaiskos, M. Tumbarello, D.P. Nicolau, P.L. Viale & G. Poulakou. (2018) Management of KPC-producing Klebsiella pneumoniae infections. Clinical Microbiology and Infection 24:2, pages 133-144.
Crossref
Crossref
Kirati Kengkla, Khachen Kongpakwattana, Surasak Saokaew, Anucha Apisarnthanarak & Nathorn Chaiyakunapruk. (2018) Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. Journal of Antimicrobial Chemotherapy 73:1, pages 22-32.
Crossref
Crossref
Yongbo Zhang, Peizhen Li, Yuhan Yin, Fuqiang Li & Qinghua Zhang. (2016) In vitro activity of tigecycline in combination with rifampin, doripenem or ceftazidime against carbapenem-resistant Klebsiella pneumoniae bloodstream isolates. The Journal of Antibiotics 70:2, pages 193-195.
Crossref
Crossref
N. L. Parchem, K. A. Bauer, C. H. Cook, J. E. Mangino, C. D. Jones, K. Porter & C. V. Murphy. (2016) Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia. European Journal of Clinical Microbiology & Infectious Diseases 35:9, pages 1433-1439.
Crossref
Crossref
Elizabeth CerceoSteven B. DeitelzweigBradley M. ShermanAlpesh N. Amin. (2016) Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microbial Drug Resistance 22:5, pages 412-431.
Crossref
Crossref
Xiaoxia Zhong, Erhu Zhao, Chunling Tang, Weibo Zhang, Juan Tan, Zhen Dong, Han-Fei Ding & Hongjuan Cui. (2015) Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo. Tumor Biology 37:6, pages 7615-7623.
Crossref
Crossref
Beatriz E. Ferro, Shashikant Srivastava, Devyani Deshpande, Jotam G. Pasipanodya, Dick van Soolingen, Johan W. Mouton, Jakko van Ingen & Tawanda Gumbo. (2016) Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease. Antimicrobial Agents and Chemotherapy 60:5, pages 2895-2900.
Crossref
Crossref
Rui Yang, Liang Yi, Zhen Dong, Qing Ouyang, Ji Zhou, Yi Pang, Yanan Wu, Lunshan Xu & Hongjuan Cui. (2016) Tigecycline Inhibits Glioma Growth by Regulating miRNA-199b-5p–HES1–AKT Pathway. Molecular Cancer Therapeutics 15:3, pages 421-429.
Crossref
Crossref
Wentao Ni, Yuliang Han, Jie Liu, Chuanqi Wei, Jin Zhao, Junchang Cui, Rui Wang & Youning Liu. (2016) Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections. Medicine 95:11, pages e3126.
Crossref
Crossref
Wentao Ni, Yuliang Han, Jin Zhao, Chuanqi Wei, Junchang Cui, Rui Wang & Youning Liu. (2016) Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. International Journal of Antimicrobial Agents 47:2, pages 107-116.
Crossref
Crossref
Neelam YanejaHarsimran Kaur. (2016) Insights into Newer Antimicrobial Agents against Gram-negative Bacteria. Microbiology Insights 9, pages MBI.S29459.
Crossref
Crossref
Arianna Pompilio, Serena De Nicola, Valentina Crocetta, Simone Guarnieri, Vincenzo Savini, Edoardo Carretto & Giovanni Di Bonaventura. (2015) New insights in Staphylococcus pseudintermedius pathogenicity: antibiotic-resistant biofilm formation by a human wound-associated strain. BMC Microbiology 15:1.
Crossref
Crossref
Garyphallia Poulakou, Matteo Bassetti, Elda Righi & George Dimopoulos. (2014) Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future Microbiology 9:9, pages 1053-1069.
Crossref
Crossref
Yulia Jitkova, Marcela Gronda, Rose Hurren, Xiaoming Wang, Carolyn A. Goard, Bozhena Jhas & Aaron D. Schimmer. (2014) A Novel Formulation of Tigecycline Has Enhanced Stability and Sustained Antibacterial and Antileukemic Activity. PLoS ONE 9:5, pages e95281.
Crossref
Crossref
F. Kontopidou, H. Giamarellou, P. Katerelos, A. Maragos, I. Kioumis, E. Trikka-Graphakos, C. Valakis & H.C. Maltezou. (2014) Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clinical Microbiology and Infection 20:2, pages O117-O123.
Crossref
Crossref
Young Hwa Choi. (2014) Treatment of drug resistant bacteria: new bugs, old drugs, and new therapeutic approaches. Journal of the Korean Medical Association 57:10, pages 837.
Crossref
Crossref
Armin Bauer & Mark Brönstrup. (2014) Industrial natural product chemistry for drug discovery and development. Nat. Prod. Rep. 31:1, pages 35-60.
Crossref
Crossref
Allen T. Griffin, Julie A. Harting & Diana M. Christensen. (2013) Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database. Diagnostic Microbiology and Infectious Disease 77:3, pages 273-277.
Crossref
Crossref